(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... the appointment of Dr. Alan Warrander to the ... Business Development. ,, "Dr. Warrander will be responsible ... for REOLYSIN(R)," said Dr. Brad Thompson, President and ... the design of a Phase 3 trial examining ...
(Date:12/10/2009)... 10 Endologix, Inc. (Nasdaq: ELGX ... disorders, announced today that Dan Lemaitre, former President ... Board of Directors effective December 11, 2009. ... non-independent directors. ,, Franklin D. Brown, Chairman of ... Dan Lemaitre to the Endologix Board of Directors. ...
(Date:12/10/2009)... ON, Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... life sciences product development company that identifies and ... at various stages of development, today provided an ... in the merger of Cytopia Ltd. into YM, ... 2009. The board of directors of Cytopia has ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4... the Board -, MADISON, N.J., April 24 ... Robert Essner, 60, has decided to retire,from the Company ... position,of Chairman since January 2003 and served as Wyeth,s ... of Directors has elected,Bernard Poussot, Wyeth,s President and Chief ...
... N.J., April 24 Pharmasset, Inc.,(Nasdaq: VRUS ) ... Conference being held from April 30, 2008 to May ... Schaefer Price,Pharmasset,s Chief Executive Officer, will provide an overview ... Morgan Stanley,representatives on Wednesday, April 30, 2008 at 3:40 ...
... genetics,Inc. (Nasdaq: DCGN ) today announced that it will ... to be issued on Thursday, May 1,after the close of ... live,webcast of its conference call to discuss these results and ... noon GMT/1pm,British Summer Time., The webcast can be accessed ...
Other Biology Technology:Wyeth Chairman Robert Essner Announces June 27 Retirement 2Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th 2deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results 2...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... low background fluorescence, minimal light scatter ... medium binding) polystyrene surface is hydrophobic ... passive interactions,• Is suitable primarily ... such as antibodies, that have large ...
... Sulfo SBED Protein:Protein Interaction Reagent A ... has rapidly gained traction as an in ... growing number of publications feature the exclusive ... to study a variety of issues relating ...
Biology Products:Biology NavigationMedical Navigation